Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors

Abstract

AbstractPrevious studies on lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) using various approaches have shown that both the molecules can act as intercellular signaling molecules. The discovery of the Edg subfamily of G-protein-coupled receptors (GPCRs) (later renamed LPA1–3 and S1P1–5) for these molecules has opened up a new avenue for pathophysiological research on lysophospholipids. Genetic and molecular studies on lysophospholipid GPCRs have elucidated pathophysiological impacts and roles in cellular signaling pathways. Recently, lysophospholipid GPCR genes have been used to develop receptor subtype-selective agonists and antagonists. The discovery of FTY720, a novel immune modulator, along with other chemical tools, has provided a means of elucidating the functions of each lysophospholipid GPCR on an organ and the whole body level. This communication attempts to retrospectively review the development of agonists and antagonists for lysophospholipid GPCRs, provide integrated information on pharmacological tools for lysophospholipid GPCR signaling, and speculate on future drug development.

DOI: 10.1038/aps.2010.135

Extracted Key Phrases

4 Figures and Tables

0501002011201220132014201520162017
Citations per Year

268 Citations

Semantic Scholar estimates that this publication has 268 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Im2010PharmacologicalTF, title={Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors}, author={Dong-Soon Im}, booktitle={Acta Pharmacologica Sinica}, year={2010} }